Citigroup Inc. Sells 212,663 Shares of Zoetis Inc. $ZTS

Citigroup Inc. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 24.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 672,386 shares of the company’s stock after selling 212,663 shares during the period. Citigroup Inc.’s holdings in Zoetis were worth $98,384,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Savvy Advisors Inc. boosted its holdings in Zoetis by 54.0% during the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after acquiring an additional 1,114 shares during the last quarter. CIBC Asset Management Inc raised its holdings in shares of Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after purchasing an additional 10,434 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its position in shares of Zoetis by 6.5% during the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after purchasing an additional 18,040 shares in the last quarter. Ninety One UK Ltd lifted its position in shares of Zoetis by 19.6% during the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after purchasing an additional 183,686 shares in the last quarter. Finally, Quilter Plc boosted its holdings in Zoetis by 10.2% during the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after purchasing an additional 40,615 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 1.1%

Shares of Zoetis stock opened at $128.73 on Monday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The stock has a market capitalization of $54.34 billion, a P/E ratio of 21.38, a P/E/G ratio of 1.97 and a beta of 0.96. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00. The stock’s 50-day simple moving average is $125.41 and its 200 day simple moving average is $134.64.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the previous year, the firm posted $1.40 earnings per share. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. Zoetis’s payout ratio is 35.22%.

Analyst Upgrades and Downgrades

Several research firms have commented on ZTS. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Bank of America upped their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.